Dyadic International, Inc. - a leading biotechnology platform company - has been making headlines for its cutting-edge research, development, and commercialization of enzymes and other proteins in the United States. This esteemed company leverages its patented and proprietary C1 platform and a host of other novel technologies to conduct robust research on the development and manufacturing of essential human and animal vaccines and drugs. Over the years, Dyadic International has produced an array of critical therapeutic enzymes and proteins, including monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, among others. Currently, the company offers the DYAI-100, an SARS-CoV-2-RBD antigen vaccine candidate, which is moving towards a first-in-human phase 1 clinical trial. The company aims to demonstrate the safety of a protein produced by its C1-cell protein production platform. Dyadic International has a research and development agreement with VTT Technical Research Centre of Finland, Ltd. and a strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. The company was founded in 1979 and is now headquartered in Jupiter, Florida.
Dyadic International's ticker is DYAI
The company's shares trade on the NASDAQ stock exchange
They are based in Jupiter, Florida
There are 1-10 employees working at Dyadic International
It is dyadic.com
Dyadic International is in the Healthcare sector
Dyadic International is in the Biotechnology industry
The following five companies are Dyadic International's industry peers: